Short answer
Rezolute, Inc. (RZLT) filed its Q4 2025 10-Q quarterly report on Feb 12, 2026 for the quarter ended Dec 31, 2025.
Q4 2025 key financials · XBRL
- Net income
- −$23M
- −44.8% YoY · −25.5% QoQ
- EPS (diluted)
- −$0.22
- +4.3% YoY · −22.2% QoQ
Source: XBRL data from the Rezolute, Inc. (RZLT) Q4 2025 10-Q on SEC EDGAR. USD.
Rezolute, Inc. Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0 for quarter ended December 31, 2025, unchanged from $0 YoY
- R&D expenses $14.348M, up 14% from $12.627M YoY
- Worst performer sunRIZE congenital HI study, missing primary and key secondary endpoints
- Workforce reduction of 29 employees, with $1.5M severance expense
- Outlook: upLIFT topline results expected second half 2026; FDA may require additional congenital HI studies
Risk Factors
- Newly triggered litigation risk from announced securities-law investigations after sunRIZE results drove a stock-price decline
- Clinical-development risk intensified after sunRIZE failed primary and secondary endpoints
- FDA regulatory uncertainty ahead of a pre-Q2 2026 meeting on ersodetug’s potential path forward
- Capital risk from potential additional studies and clinical trials required for regulatory progress
- Data-integrity risk from preliminary results changing materially after further patient follow-up and verification
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Rezolute, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.